

6. References

- Aldaz, C.M., Liao, Q.Y., LaBate, M. & Johnston, D.A. (1996) Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. *Carcinogenesis*, **17**, 2069–2072
- Anderson, T.J., Battersby, S., King, R.J.B., McPherson, K. & Going, J.J. (1989) Oral contraceptive use influences resting breast proliferation. *Hum. Pathol.*, **20**, 1139–1144
- Ansari, G.A.S., Walker, R.D., Smart, V.B. & Smith, L.L. (1982) Further investigations of mutagenic cholesterol preparations. *Food chem. Toxicol.*, **20**, 35–41
- Ball, M.J., Ashwell, E. & Gillmer, M.D.G. (1991) Progestagen-only oral contraceptives: Comparison of the metabolic effects of levonorgestrel and norethisterone. *Contraception*, **44**, 223–233

- Barlow, S.M. & Knight, A.F. (1983) Teratogenic effects of Silastic intrauterine devices in the rat with or without added medroxyprogesterone acetate. *Fertil. Steril.*, **39**, 224–230
- Bassol, S., Garza-Flores, J., Cravioto, M.C., Diaz-Sanchez, V., Fotherby, K., Lichtenberg, R. & Perez-Palacios, G. (1984) Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. *Fertil. Steril.*, **42**, 216–222
- Biswas, R. & Vonderhaar, B.K. (1987) Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. *Cancer Res.*, **47**, 3509–3514
- Bokkenheuser, B.D., Winter, J., Mosenthal, A.C., Mosbach, E.H., McSherry, C.K., Ayengar, N.K.N., Andrews, A.W., Lebherz, W.B., III, Pienta, R.J. & Wallstein, S. (1983) Fecal steroid 21-dehydroxylase, a potential marker for colorectal cancer. *Am. J. Gastroenterol.*, **78**, 469–475
- Bonnerterre, J., Peyrat, J.P., Beuscart, R. & Demaille, A. (1990) Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer. *J. Steroid Biochem. mol. Biol.*, **37**, 977–981
- Bost, L., Dong, W., Hedges, B., Primatesta, P., Prior, G., Purdon, S. & di Salvo, P. (1997) *Health Survey for England 1995*, Vol. I, *Findings*, London, The Stationery Office, p. 254
- Botella, J., Paris, J. & Lahlou, B. (1987) The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate. *Acta endocrinol.*, **115**, 544–550
- Botella, J., Duranti, E., Duc, I., Cognet, A.M., Delansorne, R. & Paris, J. (1994) Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. *J. Steroid Biochem. mol. Biol.*, **50**, 41–47
- Botella, J., Duranti, E., Viader, V., Duc, I., Delansorne, R. & Paris, J. (1995) Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nortestosterone derivatives on endometrial Ishikawa cells. *J. Steroid Biochem. mol. Biol.*, **55**, 77–84
- Breiner, M., Romalo, G. & Schweikert, H.U. (1986) Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts. *Klin. Wochenschr.*, **64**, 732–737
- Briggs, M.H. (1975) Contraceptive steroid binding to the human uterine progesterone-receptor. *Curr. med. Res. Opin.*, **3**, 95–98
- Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1986) Oral contraceptive use and the risk of breast cancer. *New Engl. J. Med.*, **315**, 405–411
- Cappelletti, V., Miodini, P., Fioravanti, L. & DiFronzo, G. (1995) Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. *Anticancer Res.*, **15**, 2551–2555
- Catherino, W.H. & Jordan, V.C. (1995) Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. *J. Steroid Biochem. mol. Biol.*, **55**, 239–246
- Centers for Disease Control and the National Institute of Child Health and Human Development, Cancer and Steroid Hormone Study (1987) Combination oral contraceptive use and the risk of endometrial cancer. *J. Am. med. Assoc.*, **257**, 796–800

- Chi, I.-C. (1995) The progestin-only pills and the levonorgestrel-releasing IUD: Two progestin-only contraceptives. *Clin. Obstet. Gynecol.*, **38**, 872–889
- Clavel, F., Andrieu, N., Gairard, B., Brémand, A., Piana, L., Lansac, J., Bréart, G., Rumeau-Rouquette, C., Flamant, R. & Renaud, R. (1991) Oral contraceptives and breast cancer: A French case-control study. *Int. J. Epidemiol.*, **20**, 32–38
- Coezy, E., Auzan, C., Lonigro, A., Philippe, M., Menard, J. & Corvol, P. (1987) Effect of mestranol on cell proliferation and angiotensinogen production in HepG2 cells: Relation with the cell cycle and action of tamoxifen. *Endocrinology*, **120**, 133–141
- Coldham, N.G. & James, V.H.T. (1990) A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β -hydroxysteroid dehydrogenase activity. *Int. J. Cancer*, **45**, 174–178
- Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: Further results. *Contraception*, **54** (Suppl. 3), 1S–106S
- Concannon, P.W., Spraker, T.R., Casey, H.W. & Hansel, W. (1981) Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches. *Fertil. Steril.*, **36**, 373–387
- Cong, H. & Beck, L.R. (1991) Preparation and pharmacokinetic evaluation of a modified long-acting injectable norethisterone microsphere. *Adv. Contracep.*, **7**, 251–256
- Cullins, V.E. & Garcia, F.A.R. (1997) Implantable hormonal and emergency contraception. *Curr. Opin. Obstet. Gynecol.*, **9**, 169–174
- Dhall, K., Kumar, M., Rastogi, G.K. & Devi, P.K. (1977) Short-term effects of norethisterone oenanthate and medroxyprogesterone acetate on glucose, insulin, growth hormone, and lipids. *Fertil. Steril.*, **28**, 154–158
- Di Carlo, F., Gallo, E., Conti, G. & Racca, S. (1983) Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives. *J. Endocrinol.*, **98**, 385–389
- Dunkel, V.C., Pienta, R.J., Sivak, A. & Traul, K.A. (1981) Comparative neoplastic transformation responses of Balb/3T3 cells, Syrian hamster embryo cells, and Rauscher murine leukemia virus-infected Fischer 344 rat embryo cells to chemical carcinogens. *J. natl Cancer Inst.*, **67**, 1303–1315
- Dunkel, V.C., Zeiger, E., Brusick, D., McCoy, E., McGregor, D., Mortelmans, K., Rosenkranz, H.S. & Simmon, V.F. (1984) Reproducibility of microbial mutagenicity assays: I. Tests with *Salmonella typhimurium* and *Escherichia coli* using a standardized protocol. *Environ. Mutag.*, **6** (Suppl. 2), 1–254
- Eibs, H.G., Spielmann, H. and Hagele, M. (1982) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. 1. *Teratology*, **25**, 27–36
- Englund, D.E. & Johansson, E.D. (1980) Endometrial effect of oral estriol treatment in postmenopausal women. *Acta obstet. gynecol. scand.*, **59**, 449–451
- Epstein, S.S., Arnold, E., Andrea, J., Bass, W. & Bishop, Y. (1972) Detection of chemical mutagens by the dominant lethal assay in the mouse. *Toxicol. appl. Pharmacol.*, **23**, 288–325

- Ewertz, M. (1992) Oral contraceptives and breast cancer risk in Denmark. *Eur. J. Cancer*, **28A**, 1176–1181
- Fahmy, K., Abdel-Razik, M., Shaaraway, M., Al-Kholy, G., Saad, S., Wagdi, A. & Al-Azzony, M. (1991) Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. *Contraception*, **44**, 419–430
- Faundes, A. Brache, V., Tejada, A.S., Cochon, L. & Alvarez-Sanchez, F. (1991) Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. *Fertil. Steril.*, **56**, 27–31
- Frank, D.W., Kirton, K.T., Murchison, T.E., Quinlan, W.J., Coleman, M.E., Gilbertson, T.J., Feenstra, E.S. & Kimball, F.A. (1979) Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years. *Fertil. Steril.*, **31**, 340–346
- Fujimoto, J., Hori, M., Ichigo, S., Morishita, S. & Tamaya, T. (1996a) Estrogen activates migration potential of endometrial cancer cells through basement membrane. *Tumour Biol.* **17**, 48–57
- Fujimoto, J., Ichigo, S., Hori, M., Morishita, S. & Tamaya, T. (1996b) Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and alpha- and beta-catenin mRNA expressions. *J. Steroid Biochem. med. Biol.*, **57**, 275–282
- Fujimoto, J., Hori, M., Ichigo, S. & Tamaya, T. (1997) Antiestrogenic compounds inhibit estrogen-induced expression of fibroblast growth factor family (FGF-1,2, and 4) mRNA in well-differentiated endometrial cancer cells. *Eur. J. Gynaecol. Oncol.*, **18**, 497–501
- Garza-Flores, J., Rodriguez, V., Perez-Palacios, G., Virutamasen, P., Tang-Keow, P., Kongsayreepong, R., Kovacs, L., Koloszar, S. & Hall, P.E. (1987) A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of Depoprovera (Task Force of WHO). *Contraception*, **36**, 441–457
- Giudice, L.C., Milkowski, D.A., Fielder, P.J. & Irwin, J.C. (1991) Characterization of the steroid-dependence of insulin-like growth factor-binding protein-2 synthesis and mRNA expression in cultured human endometrial stromal cells. *Hum. Reprod.*, **5**, 632–640
- Gray, R.H. & Pardthaisong, T. (1991a) In utero exposure to steroid contraceptives and survival during infancy. *Am. J. Epidemiol.*, **134**, 804–811
- Gray, R.H. & Pardthaisong, T. (1991b) The authors' response to Hogue. *Am. J. Epidemiol.*, **134**, 816–817
- Hackenberg, R. & Schultz, K.D. (1996) Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. *J. Steroid Biochem. mol. Biol.*, **56**, 113–117
- Herrero, R., Brinton, L.A., Reeves, W.C., Brenes, M.M., de Britton, R.C., Tenorio, F. & Gaitan, E. (1990) Injectable contraceptives and risk of invasive cervical cancer: Evidence of an association. *Int. J. Cancer*, **46**, 5–7
- Hogue, C.J. (1991) Invited commentary: The contraceptive technology tightrope. *Am. J. Epidemiol.*, **134**, 812–817
- Hussain, S.P. & Rao, A.R. (1991) Modulatory influence of injectable contraceptive steroid medroxyprogesterone acetate on methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse. *Cancer Lett.*, **61**, 187–193

- Hyder, S.M., Murthy, L. & Stancel, G.M. (1998) Progesterin regulation of vascular endothelial growth factor in human breast cancer cells. *Cancer Res.*, **58**, 392–395
- IARC (1979) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 21, *Sex Hormones (II)*, Lyon
- Ishidate, M., Jr, ed. (1983) *The Data Book of Chromosomal Aberration Tests in Vitro on 587 Chemical Substances using a Chinese Hamster Fibroblast Cell Line (CHL Cells)*, Tokyo, Realize
- Jaffe, B., Shye, D., Harlap, S., Baras, M., Belmaker, E., Gordon, L., Magidor, S. & Fortney, J. (1990) Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate. *Paediatr. perinat. Epidemiol.*, **4**, 184–195
- Jeng, M.H. & Jordan, V.C. (1991) Growth stimulation and differential regulation of transforming growth factor- β 1 (TGF β 1), TGF β 2, and TGF β 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. *Mol. Endocrinol.*, **8**, 1120–1128
- Jeng, M.H., Parker, C.J. & Jordan, V.C. (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. *Cancer Res.* **52**, 6539–6546
- Jordan, A. (1994) Toxicology of depot medroxyprogesterone acetate. *Contraception*, **49**, 189–201
- Katz, Z., Lancet, M., Skornik, J., Chemke, J., Mogilner, B.M. & Klinberg, M. (1985) Teratogenicity of progestogens given during the first trimester of pregnancy. *Obstet. Gynecol.*, **65**, 775–780
- Kawashima, K., Nakaura, S., Nagao, S., Tanaka, S., Kuwamura, T. & Omori, Y. (1977) Virilizing activities of various steroids in female rat fetuses. *Endocrinol. Jpn.*, **24**, 77–81
- Kew, M.C., Song, E., Mohammed, A. & Hodgkinson, J. (1990) Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case-control study in South African black women. *Hepatology*, **11**, 298–302
- Kim, Y.B., Berek, J.S., Martinez-Maza, O. & Satyaswaroop, P.G. (1996) Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetone in endometrial carcinoma. *Gynecol. Oncol.*, **61**, 97–100
- Kleinman, R.L. (1990) *Hormonal Contraception*, London, IPPF Medical Publications
- Kleinman, R.L. (1996) *Directory of Hormonal Contraceptives*, London, IPPF Medical Publications
- Kontula, K., Paavonen, T., Luukkainen, T. & Andersson, L.C. (1983) Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on *in vitro* functions of human mononuclear leukocytes. *Biochem. Pharmacol.*, **32**, 1511–1518
- Kooistra, H.S., Okkens, A.C., Mol, J.A., van Garderen, E., Kirpensteijn, J. & Rijnberk, A. (1997) Lack of association of progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus. *J. Reprod. Fertil.*, **Suppl. 51**, 355–361
- van Kordelaar, J.M.G., Vermorken, A.J.M., de Weerd, C.J.M. & van Rossum, J.M. (1975) Interaction of contraceptive progestins and related compounds with the oestrogen receptor. Part II: Effect on [3 H]oestradiol binding to the rat uterine receptor *in vitro*. *Acta endocrinol.*, **78**, 165–179
- Kordon, E.C., Molinolo, A.A., Pasqualini, C.D., Pazos, P., Dran, G. & Lanari, C. (1993) Progesterone induction of mammary carcinomas in female BALB/c mice. *Breast Cancer Res. Treat.*, **28**, 29–39

- Kordon, E.C., Guerra, F., Molinolo, A.A., Elizalde, P., Charreau, E.H., Pasqualini, C.D., Montecchia, F., Pazos, P., Dran, G. & Lanari, C. (1994) Effect of sialoadenectomy on medoxyprogesterone-acetate-induced mammary carcinogenesis in BALB/c mice. Correlation between histology and epidermal-growth-factor receptor content. *Int. J. Cancer*, **59**, 196–203
- Kumasaka, T., Itoh, E., Watanabe, H., Hoshino, K., Yoshinaka, A. & Masawa, N. (1994) Effects of various forms of progestin on the endometrium of the estrogen-primed, ovariectomized rat. *Endocrine J.*, **41**, 161–169
- Labrie, C., Cusan, L., Plante, M., Lapointe, S. & Labrie, F. (1987) Analysis of the androgenic activity of synthetic 'progestins' currently used for the treatment of prostate cancer. *J. Steroid Biochem.*, **28**, 379–384
- Lanari, C., Molinolo, A.A. & Pasqualini, C.D. (1986) Induction of mammary adenocarcinomas by medoxyprogesterone acetate in BALB/c female mice. *Cancer Lett.*, **33**, 215–233
- Lande, R.E (1995) New era for injectables. *Popul. Rep.*, **23**, 1–31
- Lau, T.M., Witjaksono, J., Affandi, B. & Rogers, P.A.W. (1996a) Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. *Hum. Reprod.*, **12**, 2629–2634
- Lau, T.M., Affandi, B. & Rogers, P.A.W. (1996b) Immunohistochemical detection of cathepsin D in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle. *Mol. hum. Reprod.*, **4**, 233–237
- Lax, E.R., Baumann, P. & Schriefers, H. (1984) Changes in the activities of microsomal enzymes involved in hepatic steroid metabolism in the rat after administration of androgenic, estrogenic, progestational, anabolic and catatoxic steroids. *Biochem. Pharmacol.*, **33**, 1235–1241
- Lerner, L.J., dePhillipo, M., Yiacas, E., Brennan, D. & Borman, A. (1962) Comparison of the acetophenone derivative of 16 α ,17 α -dihydroprogesterone with other progestational steroids for masculinisation of the rat fetus. *Endocrinology*, **71**, 448–451
- Li, S., Lévesque, C., Geng, C.-S., Yan, X. & Labrie, F. (1995) Inhibitory effects of medoxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E₁)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. *Breast Cancer Res. Treat.*, **34**, 147–159
- Liang, A.P., Levenson, A.G., Layde, P.M., Shelton, J.D., Hatcher, R.A., Potts, M. & Michelson, M.J. (1983) Risk of breast, uterine corpus, and ovarian cancer in women receiving medoxyprogesterone injection. *J. Am. med. Assoc.*, **249**, 2909–2912
- Luo, S., Stojanovic, M., Labrie, C. & Labrie, F. (1997) Inhibitory effect of the novel anti-estrogen EM-800 and medoxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]-anthracene-induced mammary carcinoma in rats. *Int. J. Cancer*, **73**, 580–586
- Luthy, I.A., Begin, D.J. & Labrie, F. (1988) Androgenic activity of synthetic progestins and spiro-nolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. *J. Steroid Biochem.*, **31**, 845–852
- Markiewicz, L. & Gurrpide, E. (1994) Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by *in vitro* bioassays with human cells. *J. Steroid Biochem. mol. Biol.*, **48**, 89–94

- Markiewicz, L., Hochberg, R.B. & Gurpide, E. (1992) Intrinsic estrogenicity of some progestagenic drugs. *J. Steroid Biochem. mol. Biol.*, **41**, 53–58
- Maudelonde, T., Lavaud, P., Salazar, G., Laffargue, F. & Rochefort, H. (1991) Progestin treatment depresses estrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. *Breast Cancer Res. Treat.*, **19**, 95–102
- McCauley, A. & Geller, J. (1992) Decisions for Norplant programs. *Popul. Rep.*, **24**, 1–31
- McLaughlin, L. (1982) *The Pill, John Rock and the Church*, Toronto, Little, Brown & Co., pp. 138–145
- Meirik, O., Lund, E., Adami, H.O., Bergstrom, R., Christoffersen, T. & Bergsjø, P. (1986) Oral contraceptive use and breast cancer in young women. *Lancet*, **ii**, 650–654
- Melo J.F. & Coutinho, E.M. (1977) Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. *Contraception*, **15**, 627–633
- Meyer, W.J., Walker, P.A., Wideking, C., Money, J., Kowarski, A.A., Migeon, C.J. & Borgaonkar, D.S. (1977) Pituitary function in adult males receiving medroxyprogesterone acetate. *Fertil. Steril.*, **28**, 1072–1076
- Misdorp, W. (1988) Canine mammary tumours: Protective effect of late ovariectomy and stimulating effect of progestins. *Vet. Q.*, **10**, 26–33
- Misdorp, W. (1991) Progestagens and mammary tumors in dogs and cats. *Acta endocrinol.*, **125**, 27–31
- Mitsumori, K., Furukawa, F., Sato, M., Yoshimura, H., Imazawa, T., Nishikawa, A. & Takahashi, M. (1994) Promoting effects of ethinyl estradiol on development of renal proliferative lesions induced by *N*-nitrosobis(2-oxopropyl)amine in female Syrian golden hamsters. *Cancer Res. clin. Oncol.*, **120**, 131–136
- Mol, J.A., Henzen-Logmans, S.C., Hageman, P., Misdorp, W., Blankenstein, M.A. & Rijnberk, A. (1995a) Expression of the gene encoding growth hormone in the human mammary gland. *J. clin. Endocrinol. Metab.*, **80**, 3094–3096
- Mol, J.A., van Darderen, E., Selman, P.J., Wolfswinkel, J., Rijnberk, A. & Rutteman, G.R. (1995b) Growth hormone mRNA in mammary gland tumors of dogs and cats. *J. clin. Invest.*, **95**, 2028–2034
- Mol, J.A., van Garderen, E., Rutteman, G.R. & Rijnberk, A. (1996) New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary gland of dogs, cats and humans. *J. Steroid Biochem. mol. Biol.*, **57**, 67–71
- Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N. & Dosne Pasqualini, C. (1987) Mouse mammary tumors induced by medroxyprogesterone acetate: Immunohistochemistry and hormonal receptors. *J. natl Cancer Inst.*, **79**, 1341–1350
- Musgrove, E.A., Lee, C.S.L. & Sutherland, R.L. (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α , epidermal growth factor receptor, *c-fos*, and *c-myc* genes. *Mol. cell. Biol.*, **11**, 5032–5043
- Neumann, I., Thierau, D., Andrae, U., Greim, H. & Schwartz, L.R. (1992) Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ -glutamyltranspeptidase-positive cells. *Carcinogenesis*, **13**, 373–378

- New Zealand Contraception and Health Study Group (1994) Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices, or depot-medroxyprogesterone acetate. *Contraception*, **50**, 431–441
- Nisker, J.A., Kirk, M.E. & Nunez-Troconis, J.T. (1988) Reduced incidence of rabbit endometrial neoplasia with levonorgestrel implant. *Am. J. Obstet. Gynecol.*, **158**, 300–303
- Niwa, K., Morishita, S., Murase, T., Itoh, N., Tanaka, T., Mori, H. & Tamaya, T. (1995) Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis. *Jpn. J. Cancer Res.*, **86**, 724–729
- Odlind, V., Weiner, E., Victor, A. & Johansson, E.D. (1980) Effects of sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. *Br. J. Obstet. Gynaecol.*, **87**, 416–421
- Ortiz, A., Hiroi, M., Stanczyk, F.Z., Goebelsmann, U. & Mishell, D.R., Jr (1977) Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injections of Depo-MPA. *J. clin. Endocrinol. Metab.*, **44**, 32–38
- van Os, J.L., van Laar, P.H., Oldenkamp, E.P. & Verschoor, J.S. (1981) Oestrus control and the incidence of mammary nodules in bitches, a clinical study with two progestogens. *Vet. Q.*, **3**, 46–56
- Østerlind, A., Tucker, M.A., Stone, B.J. & Jensen, O.M. (1988) The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. *Int. J. Cancer*, **42**, 821–824
- Pardthaisong, T. & Gray, R.H. (1991) In utero exposure to steroid contraceptives and outcome of pregnancy. *Am. J. Epidemiol.*, **134**, 795–803
- Pardthaisong, T., Yenchit, C. & Gray, R.H. (1992) The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. *Contraception*, **45**, 313–324
- Parzefall, W., Monschau, P. & Schulte-Hermann, R. (1989) Induction by cyproterone acetate of DNA synthesis and mitosis in primary cultures of adult rat hepatocytes in serum free medium. *Arch. Toxicol.*, **63**, 456–461
- Pater, A., Bayatpour, M. & Pater, M.M. (1990) Oncogenic transformation by human papilloma virus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. *Am. J. Obstet. Gynecol.*, **162**, 1099–1103
- Paul, C., Skegg, D.C.G. & Spears, G.F.S. (1989) Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. *Br. med. J.*, **299**, 759–762
- Paul, C., Skegg, D.C.G. & Spears, G.F.S. (1990) Oral contraceptives and risk of breast cancer. *Int. J. Cancer*, **46**, 366–373
- Paul, C., Skegg, D.C.G. & Williams, S. (1997) Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation. *Contraception*, **56**, 209–214
- Pazos, P., Lanari, C., Meiss, R., Charreau, E.H. & Pasqualini, C.D. (1991) Mammary carcinogenesis induced by *N*-methyl-*N*-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice. *Breast Cancer Res. Treat.*, **20**, 133–138
- Pazos, P., Lanari, C., Eizalde, P., Montecchia, F., Charreau, E.H. & Molinolo, A.A. (1998) Promoter effect of medroxyprogesterone acetate (MPA) in *N*-methyl-*N*-nitrosourea (MNU) induced mammary tumors in BALB/c mice. *Carcinogenesis*, **19**, 529–531

- Peek, M.J., Markham, R. & Fraser, I.S. (1995) The effects of natural and synthetic sex steroids on human decidual endothelial cell proliferation. *Hum. Reprod.*, **10**, 2238–2243
- Pekonen, F., Nyman, T. & Rutanen, E.M. (1994) Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. *Mol. cell. Endocrinol.*, **103**, 165–170
- Phillips, A., Hahn, D.W., Klimek, S. & McGuire, J.L. (1987) A comparison of the potencies and activities of progestogens used in contraceptives. *Contraception*, **36**, 181–192
- Piper, J.M. & Kennedy, D.L. (1987) Oral contraceptives in the United States: Trends in content and potency. *Int. J. Epidemiol.*, **16**, 215–221
- Population Council (1994) Syria 1993: Results from the PAPCHILD Survey. *Stud. Fam. Plann.*, **25**, 248–252
- Population Council (1995) Sudan 1992/93: Results from the PAPCHILD Health Survey. *Stud. Fam. Plann.*, **26**, 116–120
- Population Council (1996a) Bolivia 1994: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **27**, 172–176
- Population Council (1996b) Morocco 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **27**, 344–348
- Population Council (1997a) Uganda 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 156–160
- Population Council (1997b) Egypt 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 251–255
- Population Council (1997c) Guatemala 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 151–155
- Population Council (1997d) Kazakstan 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 256–260
- Population Council (1997e) Eritrea 1995: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 336–340
- Population Council (1997f) Mali 1995–96: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **28**, 341–345
- Population Council (1998a) Benin 1996: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **29**, 83–87
- Population Council (1998b) Brazil 1996: Results from the Demographic and Health Survey. *Stud. Fam. Plann.*, **29**, 88–92
- Prahalada, S., Carroad, E., Cukierski, M. & Hendrickx, A.G. (1985) Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (*Macaca fascicularis*). *Teratology*, **32**, 421–432
- Prost-Avallet, O., Oursin, J. & Adessi, G. (1991) *In vitro* effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. *J. Steroid Biochem. mol. Biol.*, **39**, 967–973
- Reynolds, J.E.F., ed. (1996) *Martindale: The Extra Pharmacopoeia*, 31st Ed., London, The Pharmaceutical Press, pp. 1495–1496, 1500–1501

- Rosenberg, L., Palmer, J.R., Zauber, A.G., Warshauer, M.E., Lewis, J.L., Jr, Strom, B.L., Harlap, S. & Shapiro, S. (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. *Am. J. Epidemiol.*, **139**, 654–661
- Russo, I.H. & Russo, J. (1991) Progestagens and mammary gland development: Differentiation versus carcinogenesis. *Acta endocrinol.*, **125**, 7–12
- Russo, I.H., Gimotty, P., Dupuis, M. & Russo, J. (1989a) Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis. *Br. J. Cancer*, **59**, 210–216
- Russo, I.H., Frederick, J. & Russo, J. (1989b) Hormone prevention of mammary carcinogenesis by norethynodrel-mestranol. *Breast Cancer Res. Treat.*, **14**, 43–56
- Rutanen, E.M., Salmi, A. & Nyman, T. (1997) mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. *Mol. hum. Reprod.*, **9**, 749–754
- Sasaki, M., Sugimura, K., Yoshida, M.A. & Aber, S. (1980) Cytogenetic effects of 60 chemicals on cultured human and Chinese hamster cells. *Kromosomo*, **20**, 574–584
- Schardein, J.L. (1980) Congenital abnormalities and hormones during pregnancy: A clinical review. *Teratology*, **22**, 251–270
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995a) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 423–437
- Schoonen, W.G.E.J., Joosten, J.W.H. & Kloosterboer, H.J. (1995b) Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. *J. Steroid Biochem. mol. Biol.*, **55**, 439–444
- Schulte-Hermann, R., Ochs, H., Bursch, W. & Parzefall, W. (1988) Quantitative structure-activity studies on effects of sixteen different steroids on growth and monooxygenases of rat liver. *Cancer Res.*, **48**, 2462–2468
- Segal, S.J., Alvarez-Sanchez, F., Brache, V., Faundes, A., Vilja, P. & Tuohimaa, P. (1991) Norplant® implants: The mechanism of contraceptive action. *Fertil. Steril.*, **56**, 273–277
- Selman, P.J., Mol, J.A., Rutteman, G.R., van Garderen, E. & Rijnberk, A.D. (1994) Progestin-induced growth hormone excess in the dog originates in the mammary gland. *Endocrinology*, **134**, 287–292
- Selman, P.J., van Garderen, E., Mol, J.A. & van den Ingh, T.S. (1995) Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. *Veter. Q.*, **17**, 128–133
- Selman, P.J., Wolfswinkel, J. & Mol, J.A. (1996) Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. *Steroids*, **61**, 133–137
- Shaaban, M.M., Elwan, S.I., El-Kabsh, M.Y., Farghaly, S.A. & Thabet, N. (1984) Effect of levonorgestrel contraceptive implants, Norplant®, on blood coagulation. *Contraception*, **30**, 421–450
- Shapiro, S.S., Dyer, R.D. & Colas, A.E. (1978) Synthetic progestins: In vitro potency on human endometrium and specific binding to cytosol receptor. *Am. J. Obstet. Gynecol.*, **132**, 549–554

- Shifren, J.L., Tseng, J.F., Zaloudek, C.J., Ryan, I.P., Meng, Y.G., Ferrara, N., Jaffe, R.B. & Taylor, R.N. (1996) Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. *J. clin. Endocrinol. Metab.*, **8**, 3112–3118
- Silvin, I., Stern, J., Diaz, S., Pavéz, M., Alvarez-Sanchez, F., Brache, V., Mishell, D.R., Macarra, M., McCarthy, T., Holma, P., Darney, P., Klaisle, C., Olsson, S.E. & Odland, V. (1992) Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. *Am. J. Obstet. Gynecol.*, **166**, 1208–1213
- Skegg, D.C., Noonan, E.A., Paul, C., Spears, G.F.S., Meirik, O. & Thomas, D.B. (1995) Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. *J. Am. med. Assoc.*, **273**, 799–804
- Skegg, D.C., Paul, C., Spears, G.F.S. & Williams, S.M. (1996) Progestogen-only oral contraceptives and risk of breast cancer in New Zealand. *Cancer Causes Control*, **7**, 513–519
- Soufir, J.-C., Jouannet, P., Marson, J. & Soumah, A. (1983) Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. *Endocrinologia*, **102**, 625–632
- Stenchever, M.A., Jarvis, J.A. & Kreger, N.K. (1969) Effect of selected estrogens and progestins on human chromosomes in vitro. *Obstet. Gynecol.*, **34**, 249–252
- Subakir, S.B., Hadisaputra, W., Siregar, B., Irawati, D., Santoso, D.I., Cornain, S. & Affandi, B. (1995) Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception. *Hum. Reprod.*, **10**, 2579–2583
- Subakir, S.B., Hadisaputra, W., Handoyo, A.E. & Affandi, B. (1996) Endometrial angiogenic response in Norplant users. *Hum. Reprod.*, **11**, 51–55
- Sutherland, R.L., Hall, R.E., Pang, G., Sutherland, R.L., Hall, R.E., Pang, G.Y., Musgrove, E.A. & Clarke, C.L. (1988) Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. *Cancer Res.*, **48**, 5084–5091
- Swenberg, J.A. (1981) Utilization of the alkaline elution assay as a short-term test for chemical carcinogens. In: Stich, H.F. & San, R.H.C., eds, *Short-term Tests for Chemical Carcinogens*, New York, Springer-Verlag, pp. 48–58
- Tarara, R. (1984) The effect of medroxyprogesterone acetate (Depo-provera) on prenatal development in the baboon (*Papio anubis*): A preliminary study. *Teratology*, **30**, 181–185
- Thomas, D.B., Ye, Z., Ray, R.M. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1995a) Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). *Contraception*, **51**, 25–31
- Thomas, D.B., Ray, R.M. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1995b) Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. *Contraception*, **52**, 307–312
- Thorogood, M. & Villard-Mackintosh, L. (1993) Combined oral contraceptives: Risks and benefits. *Br. med. Bull.*, **49**, 124–139
- Tiltman, A.J. (1985) The effect of progestins on the mitotic activity of uterine fibromyomas. *Int. J. Gynecol. Pathol.*, **4**, 89–96

- Topham, J.C. (1980) Do induced sperm-head abnormalities in mice specifically identify mammalian mutagens rather than carcinogens? *Mutat. Res.*, **74**, 379–387
- Treiman, K., Liskin, L., Kols, A. & Ward, R. (1995) IUDs—An update. *Popul. Rep.*, **23**, 1–35
- Tseng, L. & Zhu, H.H. (1997) Regulation of progesterone receptor messenger ribonucleic acid by progestin in human endometrial stromal cells. *Biol. Reprod.*, **57**, 1360–1366
- Tsutsui, T., Komine, A., Huff, J. & Barrett, J.D. (1995) Effects of testosterone, testosterone propionate, 17 β -trenbolone and progesterone on cell formation and mutagenesis in Syrian hamster embryo cells. *Carcinogenesis*, **16**, 1329–1333
- Ueda, M., Fujii, H., Yoshizawa, K., Abe, F. & Ueki, M. (1996) Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells *in vitro*. *Jpn. J. Cancer Res.*, **87**, 524–533
- UK National Case–Control Study Group (1989) Oral contraceptive use and breast cancer risk in young women. *Lancet*, **i**, 973–982
- Umapathy, E. & Rai, U.C. (1982) Effect of antiandrogens and medroxyprogesterone acetate on testicular morphometry in mice. *Acta morphol. acad. sci. hung.*, **30**, 99–108
- United States Census Bureau (1998) Int. Data Base <http://www.census.gov/ipc/www/idbacc.html>.
- Vanderboom, R.J. & Sheffield, L.G. (1993) Estrogen enhances epidermal growth factor-induced DNA synthesis in mammary epithelial cells. *J. Cell Physiol.*, **156**, 367–372
- Vessey, M., Buron, J., Doll, R., McPherson, K. & Yeates, D. (1983) Oral contraceptives and breast cancer: Final report of an epidemiologic study. *Br. J. Cancer*, **47**, 455–462
- Wharton, C. & Blackburn, R. (1988) Lower dose pills. *Popul. Rep.*, **16**, 1–31
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991a) Breast cancer and depot medroxyprogesterone acetate: A national study. *Lancet*, **338**, 833–838
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991b) Depot medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. *Int. J. Cancer*, **49**, 186–190
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991c) Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. *Int. J. Cancer*, **49**, 191–195
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991d) Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. *Int. J. Cancer*, **49**, 182–185
- WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1992) Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. *Contraception*, **45**, 299–312
- WHO Family Planning and Population Unit (1996) Family planning methods: New guidance. *Popul. Rep.*, **24**, 1–48
- Wikström, A., Green, B. & Johansson, E.D.B. (1984) The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses. *Acta obstet. gynecol. scand.*, **63**, 163–168
- Willcox, D.L., Yovich, J.L., McColm, S.C. & Schmitt, L.H. (1985) Changes in total and free concentrations of steroid hormones in the plasma of women throughout pregnancy: Effects of medroxyprogesterone acetate in the first trimester. *J. Endocrinol.*, **107**, 293–300
- Yamamoto, T., Terada, N., Nishizawa, Y. & Petrow, V. (1994) Angiostatic activities of medroxyprogesterone acetate and its analogues. *Int. J. Cancer*, **56**, 393–399

- Yovich, J.L., Willcox, D.L., Wilkinson, S.P., Poletti, V.M. & Hähnel, R. (1985) Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy. *J. Endocrinol.*, **104**, 453–459
- Yovich, J.L., Turner, S.R. & Draper, R. (1988) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. *Teratology*, **38**, 135–144
- Zalanyi, S., Jr, Aedo, A.R., Johannisson, E., Landgren, B.M. & Diczfalusy, E. (1986) Pituitary, ovarian and endometrial effects of graded doses of medroxyprogesterone acetate administered on cycle days 7 to 10. *Contraception*, **33**, 567–578